Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma

Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma

2024 | Sami Fares, Chase J. Wehrle, Hanna Hong, Keyue Sun, Chunbao Jiao, Mingyi Zhang, Abby Gross, Erlind Allkushi, Melis Uysal, Suneel Kamath, Wen Wee Ma, Jamak Modaresi Esfeh, Maureen Whitsett Linganna, Mazhar Khalil, Alejandro Pita, Jaekeun Kim, R. Matthew Walsh, Charles Miller, Koji Hashimoto, Andrea Schlegel, David Choon Hyuck Kwon, Federico Aucejo
This review article updates physicians on the available biomarker tests for the surveillance and follow-up of hepatocellular carcinoma (HCC). The goal is to provide an update on newly emerging tests and their diagnostic accuracy compared to standard protocols. The article highlights the limitations of traditional biomarkers like serum alpha-fetoprotein (AFP) and discusses the potential of new biomarkers such as circulating tumor DNA (ctDNA), genomic glycosylation, and non-invasive salivary metabolomics and microRNAs. These emerging biomarkers show promise for early detection and long-term surveillance but require large-scale prospective validation to confirm their clinical validity. The review also covers the use of these biomarkers in post-transplant prognosis and post-operative surveillance, emphasizing the importance of further research and clinical investigation.This review article updates physicians on the available biomarker tests for the surveillance and follow-up of hepatocellular carcinoma (HCC). The goal is to provide an update on newly emerging tests and their diagnostic accuracy compared to standard protocols. The article highlights the limitations of traditional biomarkers like serum alpha-fetoprotein (AFP) and discusses the potential of new biomarkers such as circulating tumor DNA (ctDNA), genomic glycosylation, and non-invasive salivary metabolomics and microRNAs. These emerging biomarkers show promise for early detection and long-term surveillance but require large-scale prospective validation to confirm their clinical validity. The review also covers the use of these biomarkers in post-transplant prognosis and post-operative surveillance, emphasizing the importance of further research and clinical investigation.
Reach us at info@study.space
[slides] Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma | StudySpace